Major depressive disorder affects about 6-16% of the world’s population and even leads to suicide. Antidepressants targeting the monoamine system require prolonged treatment over weeks or months and ...
These images demonstrate the different binding sites in NMDA receptors that the UB team has discovered are responsible for ketamine’s distinct clinical effects, as an anesthetic at high doses and as ...
New research addresses a gap in understanding how ketamine's impact on individual neurons leads to pervasive and profound changes in brain network function. A World Health Organization Essential ...
Ketamine, a decades-old anesthetic drug, holds much promise as a new antidepressant. It acts more quickly than traditional antidepressants—on the order of hours rather than weeks—and helps people for ...
University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication, often described as a wonder drug, alleviates symptoms ...
Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings ...
BUFFALO, N.Y. — University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication, often described as a wonder drug, ...
BUFFALO, N.Y. — University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication, often described as a wonder drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results